# Zinc, copper, and magnesium in premenstrual disorders: a narrative review

**Authors:** Anna Julia Krupa, Magdalena Zybała-Pawłowska, Michał Kania, Justyna Turek, Bernadeta Szewczyk, Andreas M. Grabrucker, Marcin Siwek

PMC · DOI: 10.1007/s43440-025-00791-w · 2025-10-15

## TL;DR

This review explores how zinc, copper, and magnesium may influence premenstrual disorders and mood through their roles in brain signaling and hormone regulation.

## Contribution

The paper reviews how zinc, copper, and magnesium may affect PMD through serotonin and GABA/glutamate pathways, linking them to mood regulation.

## Key findings

- Zinc, copper, and magnesium levels are associated with premenstrual disorder symptoms.
- Supplementation with these trace elements may alleviate PMD symptoms.
- Current research suggests a link between trace element imbalances and mood dysregulation in PMD.

## Abstract

Premenstrual disorders (PMD) are a prevalent health issue and often co-occur with mood disorders. The pathophysiology of PMD has not yet been thoroughly described. Two mechanisms appear to be crucial in PMD: (1) lower estrogen levels during the luteal phase, leading to a subsequent decrease in serotonin (5-HT) transmission, and (2) reduced sensitivity to allopregnanolone, resulting in an imbalance in γ-aminobutyric acid (GABA)/glutamate signaling and an increase in hypothalamic-pituitary-adrenal (HPA) activation. The roles of zinc (Zn), copper (Cu), and magnesium (Mg) in mood disorders are well-established, and they appear to be associated with PMD through similar pathways. Therefore, this narrative review provides background information on the roles of Zn, Cu, and Mg in mood regulation and discusses the impact of these trace elements on this process. The results presented, summarizing data from studies: (1) exploring the associations between Zn, Cu, and Mg levels and PMD, and (2) verifying the effects of Zn, Cu, and Mg supplementation on PMD symptoms. Finally, the caveats of current PMD research and the implications of the available data for everyday clinical practice are discussed.

Clinical trial number: Not applicable.

## Linked entities

- **Chemicals:** zinc (PubChem CID 23994), copper (PubChem CID 23978), magnesium (PubChem CID 5462224), serotonin (PubChem CID 5202), allopregnanolone (PubChem CID 92786), γ-aminobutyric acid (PubChem CID 119), GABA (PubChem CID 119), glutamate (PubChem CID 611)

## Full-text entities

- **Diseases:** disorders (MESH:D009358)
- **Chemicals:** Zinc (MESH:D015032), magnesium (MESH:D008274), copper (MESH:D003300)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12647176/full.md

---
Source: https://tomesphere.com/paper/PMC12647176